Recently published data suggest that clinical benign prostatic hyperplasia (BPH), which is
hallmarked by the occurrence of moderate-to-severe lower urinary tract symptoms (LUTS), …

CONTEXT: Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors
(PDE5-Is) have showed significant improvements in both lower urinary tract symptoms (…

Purpose: Benign prostatic hyperplasia (BPH) is a histologic diagnosis describing proliferation
of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence …

Background Benign prostatic hyperplasia is commonly treated with alpha-adrenergic–receptor
antagonists (alpha-blockers) or 5α-reductase inhibitors. The long-term effect of these …

Purpose : To revise the 2003 version of the American Urological Association's (AUA) Guideline
on the management of benign prostatic hyperplasia (BPH). Materials and Methods : From …

Purpose : The purpose of this guideline is to provide a clinical strategy for the diagnosis and
treatment of erectile dysfunction. Materials and Methods : A systematic review of the …

Purpose : We evaluated neurogenic erectile dysfunction, focusing on the post-radical
prostatectomy model. We investigated changes in DNA, protein and apoptotic cells of the rat penis …

Purpose : We assessed the efficacy and safety of tadalafil dosed once daily for lower urinary
tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods : …

Purpose : We evaluated sildenafil for erectile dysfunction and lower urinary tract symptoms
in men with the 2 conditions. Materials and Methods : This was a 12-week, double-blind, …

Purpose: Surgical therapies for symptomatic bladder outlet obstruction (BOO) due to benign
prostatic hyperplasia (BPH) are many, and vary from minimally invasive office based to high-…